{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:28:42Z","timestamp":1790771322248,"version":"4.1.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004320","name":"Shiraz University of Medical Sciences","doi-asserted-by":"publisher","award":["26525"],"award-info":[{"award-number":["26525"]}],"id":[{"id":"10.13039\/501100004320","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s13346-022-01251-1","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T14:03:48Z","timestamp":1666188228000},"page":"705-715","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Pulmonary drug delivery: an effective and convenient delivery route to combat COVID-19"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4071-9031","authenticated-orcid":false,"given":"Shohreh","family":"Alipour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3866-8519","authenticated-orcid":false,"given":"Laleh","family":"Mahmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2618-4886","authenticated-orcid":false,"given":"Fatemeh","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,19]]},"reference":[{"key":"1251_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.rmed.2017.01.006","volume":"124","author":"P Rogliani","year":"2017","unstructured":"Rogliani P, Calzetta L, Coppola A, Cavalli F, Ora J, Puxeddu E, et al. Optimizing drug delivery in COPD: the role of inhaler devices. Respir Med. 2017;124:6\u201314.","journal-title":"Respir Med."},{"key":"1251_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ejim.2020.02.023","volume":"75","author":"C Sorino","year":"2020","unstructured":"Sorino C, Negri S, Spanevello A, Visca D, Scichilone N. Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler. Eur J Intern Med. 2020;75:15\u20138.","journal-title":"Eur J Intern Med"},{"issue":"1","key":"1251_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.rmed.2007.07.031","volume":"102","author":"JC Virchow","year":"2008","unstructured":"Virchow JC, Crompton GK, Dal Negro R, Pedersen S, Magnan A, Seidenberg J, et al. Importance of inhaler devices in the management of airway disease. Respir Med. 2008;102(1):10\u20139.","journal-title":"Respir Med."},{"issue":"5","key":"1251_CR4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1080\/1120009X.2015.1105624","volume":"28","author":"S Alipour","year":"2016","unstructured":"Alipour S, Montaseri H, Khalili A, Tafaghodi M. Non-invasive endotracheal delivery of paclitaxel-loaded alginate microparticles. Journal of Chemotherapy. 2016;28(5):411\u20136.","journal-title":"Journal of Chemotherapy."},{"issue":"2","key":"1251_CR5","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.colsurfb.2010.07.050","volume":"81","author":"S Alipour","year":"2010","unstructured":"Alipour S, Montaseri H, Tafaghodi M. Preparation and characterization of biodegradable paclitaxel loaded alginate microparticles for pulmonary delivery. Colloids and Surfaces B: Biointerfaces. 2010;81(2):521\u20139.","journal-title":"Colloids and Surfaces B: Biointerfaces."},{"issue":"2","key":"1251_CR6","first-page":"336","volume":"12","author":"E Parhizkar","year":"2022","unstructured":"Parhizkar E, Sadeghinia D, Hamishehkar H, Yaqoubi S, Nokhodchi A, Alipour S. Carrier effect in development of rifampin loaded proliposome for pulmonary delivery: a quality by design study. Adv Pharm Bull. 2022;12(2):336\u201345.","journal-title":"Adv Pharm Bull."},{"issue":"4","key":"1251_CR7","doi-asserted-by":"publisher","first-page":"258","DOI":"10.22159\/ijap.2020v12i4.37453","volume":"12","author":"S Alipour","year":"2020","unstructured":"Alipour S, Shirooee A, Ahmadi F. Porogen effects on aerosolization properties of fluconazole loaded plga large porous particles. Int J Appl Pharm. 2020;12(4):258\u201363.","journal-title":"Int J Appl Pharm"},{"key":"1251_CR8","doi-asserted-by":"crossref","unstructured":"Chaurasiya B, Zhao Y-Y. Dry powder for pulmonary delivery: a comprehensive review. Pharmaceutics. 2021;13(1).","DOI":"10.3390\/pharmaceutics13010031"},{"issue":"7","key":"1251_CR9","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3109\/02652048.2014.944949","volume":"32","author":"S Alipour","year":"2015","unstructured":"Alipour S, Montaseri H, Tafaghodi M. Inhalable, large porous PLGA microparticles loaded with paclitaxel: preparation, in vitro and in vivo characterization. Journal of Microencapsulation. 2015;32(7):661\u20138.","journal-title":"Journal of Microencapsulation."},{"issue":"2","key":"1251_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0954-6111(96)90201-2","volume":"90","author":"S Pedersen","year":"1996","unstructured":"Pedersen S. Inhalers and nebulizers: which to choose and why. Respir Med. 1996;90(2):69\u201377.","journal-title":"Respir Med."},{"key":"1251_CR11","unstructured":"Gregory KL, Wilken L, Hart MK. Pulmonary disease aerosol delivery devices. 3rd ed: Am Assoc Resp Care. 2017."},{"issue":"4","key":"1251_CR12","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.rmed.2012.12.007","volume":"107","author":"J Sanchis","year":"2013","unstructured":"Sanchis J, Corrigan C, Levy ML, Viejo JL. Inhaler devices \u2013 from theory to practice. Respir Med. 2013;107(4):495\u2013502.","journal-title":"Respir Med."},{"key":"1251_CR13","doi-asserted-by":"publisher","first-page":"175346662095436","DOI":"10.1177\/1753466620954366","volume":"14","author":"S Sethi","year":"2020","unstructured":"Sethi S, Barjaktarevic IZ, Tashkin DP. The use of nebulized pharmacotherapies during the COVID-19 pandemic. Ther Adv Respir Dis. 2020;14:1753466620954366.","journal-title":"Ther Adv Respir Dis."},{"issue":"5","key":"1251_CR14","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1080\/17425247.2020.1739021","volume":"17","author":"M Cazzola","year":"2020","unstructured":"Cazzola M, Cavalli F, Usmani OS, Rogliani P. Advances in pulmonary drug delivery devices for the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Deliv. 2020;17(5):635\u201346.","journal-title":"Expert Opin Drug Deliv."},{"issue":"3","key":"1251_CR15","doi-asserted-by":"publisher","first-page":"219","DOI":"10.15171\/PS.2018.32","volume":"24","author":"H Hamishehkar","year":"2018","unstructured":"Hamishehkar H, Pourtahmaseb M, Babazadeh A, Alipour S. Physicochemical and aerosolization assessment of inhalable spray dried fluconazole powder. Pharm Sci. 2018;24(3):219\u201326.","journal-title":"Pharm Sci."},{"key":"1251_CR16","doi-asserted-by":"crossref","unstructured":"Abdellatif AAH, Tawfeek HM, Abdelfattah A, El-Saber Batiha G, Hetta HF. Recent updates in COVID-19 with emphasis on inhalation therapeutics: nanostructured and targeting systems.\u00a0J Drug Deliv Sci Technol. 2021:102435.","DOI":"10.1016\/j.jddst.2021.102435"},{"issue":"2","key":"1251_CR17","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.ijpharm.2014.12.009","volume":"478","author":"D-D Pham","year":"2015","unstructured":"Pham D-D, Fattal E, Tsapis N. Pulmonary drug delivery systems for tuberculosis treatment. International journal of pharmaceutics. 2015;478(2):517\u201329.","journal-title":"International journal of pharmaceutics."},{"key":"1251_CR18","doi-asserted-by":"crossref","unstructured":"Swarnakar R, Gupta NM, Halder I, Khilnani GC. Guidance for nebulization during the COVID-19 pandemic. Lung India. 2021;38(Suppl 1).","DOI":"10.4103\/lungindia.lungindia_681_20"},{"key":"1251_CR19","doi-asserted-by":"crossref","unstructured":"Smetana K, Brabek J. Role of interleukin-6 in lung complications in patients with COVID-19: therapeutic implications. In Vivo. 2020;34 Suppl 3:1589\u201392.","DOI":"10.21873\/invivo.11947"},{"issue":"2","key":"1251_CR20","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/joim.13091","volume":"288","author":"G Pascarella","year":"2020","unstructured":"Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020;288(2):192\u2013206.","journal-title":"J Intern Med."},{"key":"1251_CR21","doi-asserted-by":"crossref","unstructured":"Dhama K, Khan S, Tiwari R, Sircar S, Bhat S, Malik YS, et al. Coronavirus disease 2019-COVID-19. Clin Microbiol Rev. 2020;33(4).","DOI":"10.1128\/CMR.00028-20"},{"issue":"9","key":"1251_CR22","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1177\/0145561320920762","volume":"99","author":"A Lovato","year":"2020","unstructured":"Lovato A, de Filippis C. Clinical presentation of COVID-19: a systematic review focusing on upper airway symptoms. Ear Nose Throat J. 2020;99(9):569\u201376.","journal-title":"Ear Nose Throat J."},{"key":"1251_CR23","doi-asserted-by":"crossref","unstructured":"Baj J, Karaku\u0142a-Juchnowicz H, Teresi\u0144ski G, Buszewicz G, Ciesielka M, Sitarz E, et al. COVID-19: specific and non-specific clinical manifestations and symptoms: the current state of knowledge. J Clin Med. 2020;9(6).","DOI":"10.3390\/jcm9061753"},{"key":"1251_CR24","doi-asserted-by":"crossref","unstructured":"Fierabracci A, Arena A, Rossi P. COVID-19: a review on diagnosis, treatment, and prophylaxis. Int J Mol Sci. 2020;21(14).","DOI":"10.3390\/ijms21145145"},{"issue":"4","key":"1251_CR25","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1515\/dx-2020-0078","volume":"7","author":"M Franchini","year":"2020","unstructured":"Franchini M, Marano G, Cruciani M, Mengoli C, Pati I, Masiello F, et al. COVID-19-associated coagulopathy. Diagnosis (Berl). 2020;7(4):357\u201363.","journal-title":"Diagnosis (Berl)."},{"key":"1251_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100478","volume":"25","author":"W Fu","year":"2020","unstructured":"Fu W, Liu Y, Xia L, Li M, Song Z, Hu H, et al. A clinical pilot study on the safety and efficacy of aerosol inhalation treatment of IFN-\u03ba plus TFF2 in patients with moderate COVID-19. EClinicalMedicine. 2020;25: 100478.","journal-title":"EClinicalMedicine."},{"key":"1251_CR27","doi-asserted-by":"crossref","unstructured":"Silveira D, Prieto-Garcia JM, Boylan F, Estrada O, Fonseca-Bazzo YM, Jamal CM, et al. COVID-19: is there evidence for the use of herbal medicines as adjuvant symptomatic therapy? Frontiers in Pharmacology. 2020;11(1479).","DOI":"10.3389\/fphar.2020.581840"},{"key":"1251_CR28","doi-asserted-by":"crossref","unstructured":"Calabrese F, Pezzuto F, Fortarezza F, Hofman P, Kern I, Panizo A, et al. Pulmonary pathology and COVID-19: lessons from autopsy. The experience of European Pulmonary Pathologists. Virchows Arch. 2020;477(3):359-72.","DOI":"10.1007\/s00428-020-02886-6"},{"issue":"18","key":"1251_CR29","doi-asserted-by":"publisher","first-page":"7777","DOI":"10.1007\/s00253-020-10814-6","volume":"104","author":"X Chen","year":"2020","unstructured":"Chen X, Liao B, Cheng L, Peng X, Xu X, Li Y, et al. The microbial coinfection in COVID-19. Appl Microbiol Biotechnol. 2020;104(18):7777\u201385.","journal-title":"Appl Microbiol Biotechnol."},{"key":"1251_CR30","unstructured":"WHO Coronavirus (COVID-19) Dashboard. https:\/\/covid19.who.int\/: WHO; 2022 [Updated 26 May 2022]."},{"issue":"4","key":"1251_CR31","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1089\/jamp.2020.1622","volume":"33","author":"JP Mitchell","year":"2020","unstructured":"Mitchell JP, Berlinski A, Canisius S, Cipolla D, Dolovich MB, Gonda I, et al. Urgent appeal from International Society for Aerosols in Medicine (ISAM) during COVID-19: clinical decision makers and governmental agencies should consider the inhaled route of administration: a statement from the ISAM regulatory and standardization issues networking group. J Aerosol Med Pulm Drug Deliv. 2020;33(4):235\u20138.","journal-title":"J Aerosol Med Pulm Drug Deliv."},{"key":"1251_CR32","doi-asserted-by":"crossref","unstructured":"Lukassen S, Chua RL, Trefzer T, Kahn NC, Schneider MA, Muley T, et al. SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. Embo J. 2020;39(10):e105114-e.","DOI":"10.15252\/embj.20105114"},{"key":"1251_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijchy.2020.100034","volume":"6","author":"N Saheb Sharif-Askari","year":"2020","unstructured":"Saheb Sharif-Askari N, Saheb Sharif-Askari F, Al Heialy S, Hamoudi R, Kashour T, Hamid Q, et al. Cardiovascular medications and regulation of COVID-19 receptors expression. International Journal of Cardiology Hypertension. 2020;6: 100034.","journal-title":"International Journal of Cardiology Hypertension."},{"issue":"7","key":"1251_CR34","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.3390\/ijms21072657","volume":"21","author":"Y-F Tu","year":"2020","unstructured":"Tu Y-F, Chien C-S, Yarmishyn AA, Lin Y-Y, Luo Y-H, Lin Y-T, et al. A review of SARS-CoV-2 and the ongoing clinical trials. Int J Mol Sci. 2020;21(7):2657.","journal-title":"Int J Mol Sci."},{"key":"1251_CR35","doi-asserted-by":"crossref","unstructured":"Iacob S, Iacob DG. SARS-CoV-2 treatment approaches: numerous options, no certainty for a versatile virus. Frontiers in Pharmacology. 2020;11(1224).","DOI":"10.3389\/fphar.2020.01224"},{"key":"1251_CR36","doi-asserted-by":"crossref","unstructured":"Yang K-C, Lin J-C, Tsai H-H, Hsu C-Y, Shih V, Hu C-MJ. Nanotechnology advances in pathogen- and host-targeted antiviral delivery: multipronged therapeutic intervention for pandemic control. Drug Delivery and Translational Research. 2021;11(4):1420-37.","DOI":"10.1007\/s13346-021-00965-y"},{"key":"1251_CR37","doi-asserted-by":"crossref","unstructured":"Muslim S, Nasrin N, Alotaibi FO, Prasad G, Singh SK, Alam I, et al. Treatment options available for COVID-19 and an analysis on possible role of combination of rhACE2, angiotensin (1-7) and angiotensin (1-9) as effective therapeutic measure. SN Compr Clin Med. 2020:1-6.","DOI":"10.1007\/s42399-020-00407-9"},{"issue":"4","key":"1251_CR38","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.dsx.2020.05.022","volume":"14","author":"N Roshanravan","year":"2020","unstructured":"Roshanravan N, Ghaffari S, Hedayati M. Angiotensin converting enzyme-2 as therapeutic target in COVID-19. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020;14(4):637\u20139.","journal-title":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews."},{"issue":"7","key":"1251_CR39","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00592-020-01539-z","volume":"57","author":"SB Solerte","year":"2020","unstructured":"Solerte SB, Di Sabatino A, Galli M, Fiorina P. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19. Acta Diabetol. 2020;57(7):779\u201383.","journal-title":"Acta Diabetol."},{"issue":"8","key":"1251_CR40","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/ddr.21716","volume":"81","author":"C Colalto","year":"2020","unstructured":"Colalto C. Volatile molecules for COVID-19: a possible pharmacological strategy? Drug Development Research. 2020;81(8):950\u201368.","journal-title":"Drug Development Research."},{"key":"1251_CR41","doi-asserted-by":"crossref","unstructured":"Ahmed H. Albariqi, Rachel Yoon Kyung Chang, Waiting Tai, Wei-Ren Ke, Michael Y.T. Chow, Patricia Tang, et al. Inhalable hydroxychloroquine powders for potential treatment of COVID-19. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2021;34:1-12.","DOI":"10.1089\/jamp.2020.1648"},{"key":"1251_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2020.109783","volume":"142","author":"A Klimke","year":"2020","unstructured":"Klimke A, Hefner G, Will B, Voss U. Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection. Med Hypotheses. 2020;142: 109783.","journal-title":"Med Hypotheses."},{"key":"1251_CR43","doi-asserted-by":"crossref","unstructured":"Kavanagh O, Marie Healy A, Dayton F, Robinson S, O'Reilly NJ, Mahoney B, et al. Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19. Med Hypotheses. 2020;143:110110.","DOI":"10.1016\/j.mehy.2020.110110"},{"key":"1251_CR44","doi-asserted-by":"crossref","unstructured":"de Reus YA, Hagedoorn P, Sturkenboom MGG, Grasmeijer F, Bolhuis MS, Sibum I, et al. Tolerability and pharmacokinetic evaluation of inhaled dry powder hydroxychloroquine in healthy volunteers. medRxiv. 2020:2020.12.03.20243162.","DOI":"10.1101\/2020.12.03.20243162"},{"key":"1251_CR45","doi-asserted-by":"crossref","unstructured":"Tai W, Chow MY, Chang RY, Tang P, Gonda I, MacArthur RB, et al. Nebulised isotonic hydroxychloroquine aerosols for potential treatment of COVID-19. Pharmaceutics. 2021;13(8).","DOI":"10.3390\/pharmaceutics13081260"},{"key":"1251_CR46","doi-asserted-by":"crossref","unstructured":"Sahakijpijarn S, Moon C, Koleng JJ, Christensen DJ, Williams Iii RO. Development of remdesivir as a dry powder for inhalation by thin film freezing. Pharmaceutics. 2020;12(11).","DOI":"10.3390\/pharmaceutics12111002"},{"key":"1251_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2020.109876","volume":"144","author":"C Contini","year":"2020","unstructured":"Contini C, Enrica Gallenga C, Neri G, Maritati M, Conti P. A new pharmacological approach based on remdesivir aerosolized administration on SARS-CoV-2 pulmonary inflammation: a possible and rational therapeutic application. Med Hypotheses. 2020;144: 109876.","journal-title":"Med Hypotheses."},{"key":"1251_CR48","doi-asserted-by":"crossref","unstructured":"Gatti M, De Ponti F. Drug repurposing in the COVID-19 era: insights from case studies showing pharmaceutical peculiarities. Pharmaceutics. 2021;13(3).","DOI":"10.3390\/pharmaceutics13030302"},{"issue":"19","key":"1251_CR49","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020;383(19):1813\u201326.","journal-title":"N Engl J Med."},{"key":"1251_CR50","doi-asserted-by":"crossref","unstructured":"Yang C-J, Wei Y-J, Chang H-L, Chang P-Y, Tsai C-C, Chen Y-H, et al. Remdesivir use in the coronavirus disease 2019 pandemic: a mini-review. Journal of Microbiology, Immunology and Infection. 2020.","DOI":"10.1016\/j.jmii.2020.09.002"},{"issue":"4","key":"1251_CR51","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1208\/s12248-020-00459-8","volume":"22","author":"D Sun","year":"2020","unstructured":"Sun D. Remdesivir for treatment of COVID-19: combination of pulmonary and IV administration may offer aditional benefit. AAPS j. 2020;22(4):77.","journal-title":"Aaps j."},{"issue":"7","key":"1251_CR52","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3390\/pharmaceutics13071077","volume":"13","author":"BB Eedara","year":"2021","unstructured":"Eedara BB, Alabsi W, Encinas-Basurto D, Polt R, Ledford JG, Mansour HM. Inhalation delivery for the treatment and prevention of COVID-19 infection. Pharmaceutics. 2021;13(7):1077.","journal-title":"Pharmaceutics."},{"issue":"14","key":"1251_CR53","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2217\/nnm-2020-0475","volume":"16","author":"R Vartak","year":"2021","unstructured":"Vartak R, Patil SM, Saraswat A, Patki M, Kunda NK, Patel K. Aerosolized nanoliposomal carrier of remdesivir: an effective alternative for COVID-19 treatment in vitro. Nanomedicine. 2021;16(14):1187\u2013202.","journal-title":"Nanomedicine."},{"key":"1251_CR54","unstructured":"Pharmacokinetics of inhaled nanoparticle formulation of remdesivir (GS-5734) and NA-831 [Internet]. 2020. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04480333."},{"key":"1251_CR55","unstructured":"Study in participants with early stage coronavirus disease 2019 (COVID-19) to evaluate the safety, efficacy, and pharmacokinetics of remdesivir administered by inhalation [Internet]. 2020. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT045392622020 .\u00a0 Accessed March 2022."},{"key":"1251_CR56","doi-asserted-by":"crossref","unstructured":"\u0141agocka R, Dziedziejko V, K\u0142os P, Pawlik A. Favipiravir in therapy of viral infections. J Clin Med. 2021;10(2).","DOI":"10.3390\/jcm10020273"},{"issue":"10","key":"1251_CR57","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.3390\/ph14101059","volume":"14","author":"AS Tulbah","year":"2021","unstructured":"Tulbah AS, Lee W-H. Physicochemical characteristics and in vitro toxicity\/anti-SARS-CoV-2 activity of favipiravir solid lipid nanoparticles (SLNs). Pharmaceuticals. 2021;14(10):1059.","journal-title":"Pharmaceuticals."},{"issue":"2","key":"1251_CR58","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3390\/pharmaceutics14020300","volume":"14","author":"SN Wong","year":"2022","unstructured":"Wong SN, Weng J, Ip I, Chen R, Lakerveld R, Telford R, et al. Rational development of a carrier-free dry powder inhalation formulation for respiratory viral infections via quality by design: a drug-drug cocrystal of favipiravir and theophylline. Pharmaceutics. 2022;14(2):300.","journal-title":"Pharmaceutics."},{"issue":"1","key":"1251_CR59","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s13337-021-00679-2","volume":"32","author":"V Thakur","year":"2021","unstructured":"Thakur V, Ratho RK, Panda JJ. Respiratory delivery of favipiravir-tocilizumab combination through mucoadhesive protein-lipidic nanovesicles: prospective therapeutics against COVID-19. VirusDisease. 2021;32(1):131\u20136.","journal-title":"VirusDisease."},{"issue":"9","key":"1251_CR60","volume":"12","author":"KO Elkholy","year":"2020","unstructured":"Elkholy KO, Hegazy O, Erdinc B, Abowali H. Ivermectin: a closer look at a potential remedy. Cureus. 2020;12(9): e10378.","journal-title":"Cureus."},{"key":"1251_CR61","doi-asserted-by":"crossref","unstructured":"Mittal N, Mittal R. Inhaled route and anti-inflammatory action of ivermectin: do they hold promise in fighting against COVID-19? Med Hypotheses. 2020:110364.","DOI":"10.1016\/j.mehy.2020.110364"},{"issue":"1","key":"1251_CR62","doi-asserted-by":"publisher","first-page":"17073","DOI":"10.1038\/s41598-020-74084-y","volume":"10","author":"C Chaccour","year":"2020","unstructured":"Chaccour C, Abizanda G, Irigoyen-Barrio \u00c1, Casellas A, Aldaz A, Mart\u00ednez-Gal\u00e1n F, et al. Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats. Scientific Reports. 2020;10(1):17073.","journal-title":"Scientific Reports."},{"key":"1251_CR63","unstructured":"Okasha K. Ivermectin nasal spray for COVID19 patients https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT045102332020 [Available from: Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04510233 (Accessed on 19 June 2021)."},{"issue":"3","key":"1251_CR64","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1007\/s43440-021-00231-5","volume":"73","author":"A Cort\u00e9s-Borra","year":"2021","unstructured":"Cort\u00e9s-Borra A, Aranda-Abreu GE. Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2. Pharmacological reports\u202f: PR. 2021;73(3):962\u20135.","journal-title":"Pharmacological reports : PR."},{"issue":"3","key":"1251_CR65","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/jcph.1802","volume":"61","author":"P Grieb","year":"2021","unstructured":"Grieb P, \u015awi\u0105tkiewicz M, Prus K, Rejdak K. Amantadine for COVID-19. Journal of clinical pharmacology. 2021;61(3):412\u20133.","journal-title":"Journal of clinical pharmacology."},{"issue":"3","key":"1251_CR66","doi-asserted-by":"publisher","first-page":"260","DOI":"10.2174\/1567201818666210331121803","volume":"19","author":"N Islam","year":"2022","unstructured":"Islam N, Rahman S. Novel pulmonary delivery of antiviral drugs for treating COVID-19 in patients with Parkinson\u2019s disease. Curr Drug Deliv. 2022;19(3):260\u20135.","journal-title":"Curr Drug Deliv."},{"issue":"5","key":"1251_CR67","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1093\/infdis\/141.5.535","volume":"141","author":"FG Hayden","year":"1980","unstructured":"Hayden FG, Hall WJ, Douglas RG Jr. Therapeutic effects of aerosolized amantadine in naturally acquired infection due to influenza A virus. The Journal of Infectious Diseases. 1980;141(5):535\u201342.","journal-title":"The Journal of Infectious Diseases."},{"key":"1251_CR68","unstructured":"Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Respiratory Medicine. 2020;12."},{"key":"1251_CR69","doi-asserted-by":"crossref","unstructured":"Mary A, H\u00e9naut L, Macq PY, Badoux L, Cappe A, Por\u00e9e T, et al. Rationale for COVID-19 treatment by nebulized interferon-\u03b2-1b-literature review and personal preliminary experience. Frontiers in pharmacology. 2020;11:592543-.","DOI":"10.3389\/fphar.2020.592543"},{"key":"1251_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104791","volume":"178","author":"E Sallard","year":"2020","unstructured":"Sallard E, Lescure FX, Yazdanpanah Y, Mentre F, Peiffer-Smadja N. Type 1 interferons as a potential treatment against COVID-19. Antiviral research. 2020;178: 104791.","journal-title":"Antiviral research."},{"issue":"2","key":"1251_CR71","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/S2213-2600(20)30523-3","volume":"9","author":"N Peiffer-Smadja","year":"2021","unstructured":"Peiffer-Smadja N, Yazdanpanah Y. Nebulised interferon beta-1a for patients with COVID-19. Lancet Respir Med. 2021;9(2):122\u20133.","journal-title":"Lancet Respir Med."},{"issue":"16\u201317","key":"1251_CR72","doi-asserted-by":"publisher","first-page":"6315","DOI":"10.1007\/s00253-021-11488-4","volume":"105","author":"HA Parray","year":"2021","unstructured":"Parray HA, Shukla S, Perween R, Khatri R, Shrivastava T, Singh V, et al. Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections. Appl Microbiol Biotechnol. 2021;105(16\u201317):6315\u201332.","journal-title":"Appl Microbiol Biotechnol."},{"issue":"1","key":"1251_CR73","first-page":"10","volume":"38","author":"B Shanmugaraj","year":"2020","unstructured":"Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol. 2020;38(1):10\u20138.","journal-title":"Asian Pac J Allergy Immunol."},{"issue":"8","key":"1251_CR74","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","volume":"23","author":"RQ Le","year":"2018","unstructured":"Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. The Oncologist. 2018;23(8):943\u20137.","journal-title":"The Oncologist."},{"key":"1251_CR75","doi-asserted-by":"crossref","unstructured":"Mayor A, Thibert B, Huille S, Respaud R, Audat H, Heuz\u00e9-Vourc\u2019h N. Inhaled antibodies: formulations require specific development to overcome instability due to nebulization. Drug Delivery and Translational Research. 2021;11(4):1625-33.","DOI":"10.1007\/s13346-021-00967-w"},{"key":"1251_CR76","doi-asserted-by":"crossref","unstructured":"Halpin DMG, Singh D, Hadfield RM. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. European Respiratory Journal. 2020:2001009.","DOI":"10.1183\/13993003.01009-2020"},{"issue":"11","key":"1251_CR77","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S2213-2600(20)30447-1","volume":"8","author":"D Singh","year":"2020","unstructured":"Singh D, Halpin DMG. Inhaled corticosteroids and COVID-19-related mortality: confounding or clarifying? The Lancet Respiratory Medicine. 2020;8(11):1065\u20136.","journal-title":"The Lancet Respiratory Medicine."},{"issue":"6","key":"1251_CR78","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1164\/rccm.202005-2000LE","volume":"202","author":"B Lipworth","year":"2020","unstructured":"Lipworth B, Kuo CR, Lipworth S, Chan R. Inhaled corticosteroids and COVID-19. Am J Respir Crit Care Med. 2020;202(6):899\u2013900.","journal-title":"Am J Respir Crit Care Med."},{"issue":"6","key":"1251_CR79","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.jiac.2020.04.007","volume":"26","author":"K Iwabuchi","year":"2020","unstructured":"Iwabuchi K, Yoshie K, Kurakami Y, Takahashi K, Kato Y, Morishima T. Therapeutic potential of ciclesonide inhalation for COVID-19 pneumonia: report of three cases. Journal of Infection and Chemotherapy. 2020;26(6):625\u201332.","journal-title":"Journal of Infection and Chemotherapy."},{"issue":"2","key":"1251_CR80","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.jaci.2020.09.034","volume":"147","author":"LJ Finney","year":"2021","unstructured":"Finney LJ, Glanville N, Farne H, Aniscenko J, Fenwick P, Kemp SV, et al. Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon. J Allergy Clin Immunol. 2021;147(2):510-9.e5.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"1251_CR81","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s10787-020-00744-0","volume":"28","author":"M Asif","year":"2020","unstructured":"Asif M, Saleem M, Saadullah M, Yaseen HS, Al Zarzour R. COVID-19 and therapy with essential oils having antiviral, anti-inflammatory, and immunomodulatory properties. Inflammopharmacology. 2020;28(5):1153\u201361.","journal-title":"Inflammopharmacology."},{"key":"1251_CR82","unstructured":"Tushar P, Jayashri M, Pranali T. Inhalation of essential oils: could be adjuvant therapeutic steratey for COVID-19.\u00a0\u00a0Int J Pharm Sci Res. 2020;11(9)."},{"key":"1251_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2020.111966","volume":"148","author":"S Gowrishankar","year":"2021","unstructured":"Gowrishankar S, Muthumanickam S, Kamaladevi A, Karthika C, Jothi R, Boomi P, et al. Promising phytochemicals of traditional Indian herbal steam inhalation therapy to combat COVID-19 \u2013 an in silico study. Food and Chemical Toxicology. 2021;148: 111966.","journal-title":"Food and Chemical Toxicology."},{"key":"1251_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2020.109947","volume":"144","author":"ZA Ali","year":"2020","unstructured":"Ali ZA, El-Mallakh RS. Nebulized lidocaine in COVID-19, an hypothesis. Med Hypotheses. 2020;144: 109947.","journal-title":"Med Hypotheses."},{"issue":"3","key":"1251_CR85","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.intimp.2013.08.018","volume":"17","author":"W-S Lee","year":"2013","unstructured":"Lee W-S, Lee S-M, Kim M-K, Park S-G, Choi I-W, Choi I, et al. The tryptophan metabolite 3-hydroxyanthranilic acid suppresses T cell responses by inhibiting dendritic cell activation. International Immunopharmacology. 2013;17(3):721\u20136.","journal-title":"International Immunopharmacology."},{"issue":"3","key":"1251_CR86","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.amjms.2020.05.044","volume":"360","author":"A Brennecke","year":"2020","unstructured":"Brennecke A, Villar L, Wang Z, Doyle LM, Meek A, Reed M, et al. Is inhaled furosemide a potential therapeutic for COVID-19? The American Journal of the Medical Sciences. 2020;360(3):216\u201321.","journal-title":"The American Journal of the Medical Sciences."},{"key":"1251_CR87","doi-asserted-by":"crossref","unstructured":"Orienti I, Gentilomi GA, Farruggia G. Pulmonary delivery of fenretinide: a possible adjuvant treatment in COVID-19. Int J Mol Sci. 2020;21(11).","DOI":"10.3390\/ijms21113812"},{"key":"1251_CR88","doi-asserted-by":"crossref","unstructured":"Lana JFSD, Lana AVSD, Rodrigues QS, Santos GS, Navani R, Navani A, et al. Nebulization of glutathione and N-acetylcysteine as an adjuvant therapy for COVID-19 onset. Adv Redox Res. 2021;3.","DOI":"10.1016\/j.arres.2021.100015"},{"issue":"1","key":"1251_CR89","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1186\/s13054-020-03222-9","volume":"24","author":"G Tavazzi","year":"2020","unstructured":"Tavazzi G, Pozzi M, Mongodi S, Dammassa V, Romito G, Mojoli F. Inhaled nitric oxide in patients admitted to intensive care unit with COVID-19 pneumonia. Critical Care. 2020;24(1):508.","journal-title":"Critical Care."},{"issue":"10","key":"1251_CR90","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0239692","volume":"15","author":"P Correale","year":"2020","unstructured":"Correale P, Caracciolo M, Bilotta F, Conte M, Cuzzola M, Falcone C, et al. Therapeutic effects of adenosine in high flow 21% oxygen aereosol in patients with Covid19-pneumonia. PLOS ONE. 2020;15(10): e0239692.","journal-title":"PLOS ONE."},{"key":"1251_CR91","doi-asserted-by":"crossref","unstructured":"Wang M, Peng J, Hui J, Hou D, Li W, Yang J. Hydrogen therapy as an effective and novel adjuvant treatment against COVID-19. QJM: An International Journal of Medicine. 2020.","DOI":"10.1093\/qjmed\/hcaa301"},{"key":"1251_CR92","doi-asserted-by":"crossref","unstructured":"Saravolatz LD, Depcinski S, Sharma M. Molnupiravir and nirmatrelvir-ritonavir: oral COVID antiviral drugs. Clinical Infectious Diseases. 2022.","DOI":"10.1093\/cid\/ciac180"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-022-01251-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-022-01251-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-022-01251-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T01:28:46Z","timestamp":1675474126000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-022-01251-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,19]]},"references-count":92,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["1251"],"URL":"https:\/\/doi.org\/10.1007\/s13346-022-01251-1","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,19]]},"assertion":[{"value":"9 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agreed with the content and all gave explicit consent to submit the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}